BioPharmSignal logoBioPharmSignal

Biotech News

CVRx Reports Preliminary First Quarter 2026 Financial Results

CVRx (CVRX)CVRxEarnings

Delivered strong topline performance with first quarter revenue expected to be $14.7 million to $14.8 million, approximately 20% growth compared to first quarter of 2025 Early data in 2026 shows an increase in the 30-day approval rate for Medicare Advantage prior authorizations managed by our

Open original release

Related news

CVRXCVRx2026-05-11 20:05 EST

CVRx Reports First Quarter 2026 Financial and Operating Results

CVRXCVRx2026-04-27 20:30 EST

CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026

XTNTXtant Medical2026-05-13 11:00 EST

Xtant Medical Reports First Quarter 2026 Financial Results

ICCMIceCure Medical2026-05-12 12:30 EST

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

TMCITreace Medical Concepts2026-05-08 11:05 EST

Treace Medical Concepts Reports First Quarter 2026 Financial Results

AORTArtivion2026-05-07 20:05 EST

Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan

XTNTXtant Medical2026-05-07 12:00 EST

Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026

NAMSNewAmsterdam Pharma2026-05-07 11:00 EST

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

SGHTSight Sciences2026-05-06 20:05 EST

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance

ATRCAtriCure2026-05-05 20:01 EST

AtriCure Reports First Quarter 2026 Financial Results

View all latest news

CVRx

CVRx is a medical device company focused on neuromodulation therapies for heart failure and hypertension-related conditions. Its products aim to address cardiovascular disease through implanted device technology.

Recent company news

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

CVRXCVRx2026-05-20 20:30 EST

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

CVRXCVRx2026-05-14 12:00 EST

CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy

CVRXCVRx2026-05-11 20:05 EST

CVRx Reports First Quarter 2026 Financial and Operating Results

CVRXCVRx2026-05-04 20:30 EST

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

Stock data

Close
4.88 USD
Market cap
144.09M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States